Adagene Inc. (ADAG)
NASDAQ: ADAG
· Real-Time Price · USD
1.58
0.06 (3.95%)
At close: May 01, 2025, 3:41 PM
1.58
0.00%
After-hours: May 01, 2025, 04:00 PM EDT
3.95% (1D)
| Bid | 1.42 |
| Market Cap | 59.55M |
| Revenue (ttm) | 815.75K |
| Net Income (ttm) | -31.85M |
| EPS (ttm) | -0.74 |
| PE Ratio (ttm) | -2.14 |
| Forward PE | -1.88 |
| Analyst | Buy |
| Ask | 1.65 |
| Volume | 15,660 |
| Avg. Volume (20D) | 27,942 |
| Open | 1.53 |
| Previous Close | 1.52 |
| Day's Range | 1.50 - 1.63 |
| 52-Week Range | 1.32 - 3.58 |
| Beta | 0.61 |
About ADAG
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical tr...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 9, 2021
Employees 138
Stock Exchange NASDAQ
Ticker Symbol ADAG
Website https://www.adagene.com
Analyst Forecast
According to 1 analyst ratings, the average rating for ADAG stock is "Buy." The 12-month stock price forecast is $8, which is an increase of 406.33% from the latest price.
Stock Forecasts8 months ago
+8.86%
Adagene shares are trading higher after the compan...
Unlock content with
Pro Subscription
